India is poised to become a significant hub for breakthroughs in cancer detection, classification, and management, driven by its genetically diverse population and growing healthcare infrastructure. With global cancer cases projected to reach 35 million annually by 2050 and India facing nearly 2.5 million cases by 2045, the country's scale and adaptive policy capabilities, demonstrated in past public health successes like polio eradication and HIV/AIDS treatment access, position it uniquely. The decreasing cost of next-generation sequencing (NGS) in India, coupled with its extensive National Cancer Registry Programme and a burgeoning medical tourism sector in oncology, provides a rich dataset for genomic research. This presents an opportunity for India to lead in data-driven oncology, especially for low- and middle-income countries, by formalizing regulatory frameworks to accommodate comprehensive genomic profiling and advanced diagnostic platforms.